Pulse Biosciences, Inc. (PLSE)
Market Cap | 630.12M |
Revenue (ttm) | n/a |
Net Income (ttm) | -42.55M |
Shares Out | 55.23M |
EPS (ttm) | -0.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 169,260 |
Open | 10.77 |
Previous Close | 10.83 |
Day's Range | 10.76 - 11.83 |
52-Week Range | 3.78 - 14.96 |
Beta | 1.76 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 8, 2024 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporat... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/n/o/press10-2502301.jpg)
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation...
![](https://cdn.snapi.dev/images/v1/y/t/press3-2461190.jpg)
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation...
![](https://cdn.snapi.dev/images/v1/s/2/press6-2440402.jpg)
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) t...
![](https://cdn.snapi.dev/images/v1/v/l/press9-2434582.jpg)
Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
![](https://cdn.snapi.dev/images/v1/x/a/press2-2430737.jpg)
Pulse Biosciences Enhances Executive Leadership Team
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology (“Pulse”), today ...
![](https://cdn.snapi.dev/images/v1/3/l/press5-2421441.jpg)
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
![](https://cdn.snapi.dev/images/v1/b/h/press7-2416191.jpg)
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
![](https://cdn.snapi.dev/images/v1/9/m/conf1-2405898.jpg)
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) t...
![](https://cdn.snapi.dev/images/v1/9/u/conf4-2389332.jpg)
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
![](https://cdn.snapi.dev/images/v1/p/f/press5-2347214.jpg)
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
![](https://cdn.snapi.dev/images/v1/a/m/press6-2347215.jpg)
Pulse Biosciences Announces Plans to Initiate a Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
![](https://cdn.snapi.dev/images/v1/r/y/conf20-2325300.jpg)
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, to...
![](https://cdn.snapi.dev/images/v1/g/f/press9-2315957.jpg)
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced r...
![](https://cdn.snapi.dev/images/v1/n/o/press16-2275603.jpg)
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technol...
![](https://cdn.snapi.dev/images/v1/z/g/press17-2252851.jpg)
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for t...
![](https://cdn.snapi.dev/images/v1/h/q/press18-2213112.jpg)
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology...
![](https://cdn.snapi.dev/images/v1/r/y/press11-2203376.jpg)
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology...
![](https://cdn.snapi.dev/images/v1/n/u/press13-2166956.jpg)
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology...
![](https://cdn.snapi.dev/images/v1/x/e/conf18-2160261.jpg)
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology...
![](https://cdn.snapi.dev/images/v1/9/z/press16-2154427.jpg)
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology...
![](https://cdn.snapi.dev/images/v1/5/8/conf20-2153064.jpg)
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (ns...
![](https://cdn.snapi.dev/images/v1/s/h/conf4-2128968.jpg)
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) te...
![](https://cdn.snapi.dev/images/v1/y/f/press3-2117119.jpg)
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) te...
![](https://cdn.snapi.dev/images/v1/a/s/press14-2085621.jpg)
Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) te...
![](https://cdn.snapi.dev/images/v1/w/m/press14-2083506.jpg)
Pulse Biosciences' Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) te...